Danaher Corp (DHR)

$223.01 +0.28 (0.13%)
Market Cap 157.52B
Revenue (ttm) 23.88B
Net Income (ttm) 3.90B
EPS (ttm) N/A
PE Ratio 28.89
Forward PE 28.83
Profit Margin 16.33%
Debt to Equity Ratio 0.32
Volume 3,955,600
Avg Vol 4,244,986
Day's Range N/A - N/A
Shares Out 706.35M
Stochastic %K 63%
Beta 0.77
Analysts Strong Sell
Price Target $251.15

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 202 828 0850
Fax: 202 828 0860
Address:
2200 Pennsylvania Avenue N.W., Suite 800W, Washington, United States
nathanfrederick
nathanfrederick Oct. 25 at 7:55 PM
$PFE $DHR High volume limit https://stocktwits.com/colbertquiller/message/633715057
0 · Reply
smartkarma
smartkarma Oct. 24 at 6:04 PM
$DHR | Danaher Corporation Is Powering Ahead With Explosive Bioprocessing Growth; But These Are The 4 Biggest Challenges Ahead! "Danaher Corporation's third-quarter 2025 earnings showcased a balanced performance underpinned by solid demand in certain sectors, yet offset by..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/danaher-corporation-is-powering-ahead-with-explosive-bioprocessing-growth-but-these-are-the-4-biggest-challenges-ahead
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 23 at 10:05 PM
$DHR Share Price: $222.64 Contract Selected: Nov 14, 2025 $225 Calls Buy Zone: $3.82 – $4.73 Target Zone: $7.24 – $8.85 Potential Upside: 79% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
IN0V8
IN0V8 Oct. 23 at 2:44 PM
$DHR Wells Fargo raises target price to $230 from $205
0 · Reply
UltimateNutz
UltimateNutz Oct. 23 at 1:27 PM
$DHR the revenue ‘beat’ of $40M was aided by a pull forward of about $100M per mgmt. would have been a tad light without it. <$210
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 1:18 PM
Wells Fargo has updated their rating for Danaher ( $DHR ) to Equal-Weight with a price target of 230.
0 · Reply
ProfessorGamma
ProfessorGamma Oct. 23 at 12:44 AM
$PRSO $ABEV $CFLT $DHR How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 22 at 11:00 PM
Enter: $DHR NOV 14 2025 $220 CALLS Buy in Price: $6.20 - $8.00 Take Profit: $18.00 Stop Bleeding: $7.04 ROI Potential: 125% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 3:16 PM
TD Cowen has adjusted their stance on Danaher ( $DHR ), setting the rating to Buy with a target price of 250 → 260.
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 22 at 2:26 PM
$CDXS $DHR Interesting! https://www.aldevron.com/catalog-products/free-sample?utm_campaign=9437057-mrna-vx-tx&utm_term=codex-gmp-grade&utm_content=348143505&utm_medium=social&utm_source=linkedin&hss_channel=lcp-151339
0 · Reply
Latest News on DHR
Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights

Oct 24, 2025, 11:52 AM EDT - 1 day ago

Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights

DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 23, 2025, 4:52 PM EDT - 2 days ago

DHR Announcement: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings

Oct 22, 2025, 1:01 PM EDT - 3 days ago

These Analysts Increase Their Forecasts On Danaher Following Upbeat Q3 Earnings

Danaher: Regaining Growth Momentum

Oct 22, 2025, 10:49 AM EDT - 3 days ago

Danaher: Regaining Growth Momentum

Danaher Still A Hold: Good Q3 Results Alone Don't Make A Great Investment

Oct 22, 2025, 8:10 AM EDT - 3 days ago

Danaher Still A Hold: Good Q3 Results Alone Don't Make A Great Investment

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Oct 21, 2025, 4:45 PM EDT - 4 days ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

Oct 21, 2025, 11:14 AM EDT - 4 days ago

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?

Oct 21, 2025, 10:55 AM EDT - 4 days ago

Is Danaher's Q3 beat enough to reignite long-term growth for DHR investors?

Danaher beats quarterly estimates on strength in diagnostic tools and tech

Oct 21, 2025, 7:01 AM EDT - 5 days ago

Danaher beats quarterly estimates on strength in diagnostic tools and tech

Danaher Sales and Profit Rise on Bioprocessing Momentum

Oct 21, 2025, 6:23 AM EDT - 5 days ago

Danaher Sales and Profit Rise on Bioprocessing Momentum

Danaher Reports Third Quarter 2025 Results

Oct 21, 2025, 6:00 AM EDT - 5 days ago

Danaher Reports Third Quarter 2025 Results

Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Oct 16, 2025, 10:18 PM EDT - 9 days ago

Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

Danaher Stock: Monopoly Margins, Discounted Price

Oct 15, 2025, 10:25 AM EDT - 10 days ago

Danaher Stock: Monopoly Margins, Discounted Price

4 Stocks That Aren't Too Hot to Buy Right Now

Oct 6, 2025, 2:45 PM EDT - 19 days ago

4 Stocks That Aren't Too Hot to Buy Right Now

EVRG KNTK PWR XLU

Danaher: Balanced Portfolio With Upside Potential In 2026

Oct 1, 2025, 6:33 AM EDT - 25 days ago

Danaher: Balanced Portfolio With Upside Potential In 2026

Danaher Schedules Third Quarter 2025 Earnings Conference Call

Sep 23, 2025, 4:15 PM EDT - 4 weeks ago

Danaher Schedules Third Quarter 2025 Earnings Conference Call

Analysts' Top S&P 500 Stocks to Buy Now

Sep 11, 2025, 2:26 PM EDT - 6 weeks ago

Analysts' Top S&P 500 Stocks to Buy Now

HWM SPGI

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Sep 10, 2025, 8:31 AM EDT - 6 weeks ago

Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research

Danaher Announces Quarterly Dividend

Sep 9, 2025, 4:15 PM EDT - 6 weeks ago

Danaher Announces Quarterly Dividend

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

Sep 5, 2025, 8:39 PM EDT - 7 weeks ago

DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation - DHR

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX GRAL ILMN IONS MRNA RGEN

Danaher Stock Closes Near Day's High After Key Trading Signal

Aug 4, 2025, 7:13 AM EDT - 2 months ago

Danaher Stock Closes Near Day's High After Key Trading Signal

Danaher Appoints Jonathan Leiken as General Counsel

Jul 31, 2025, 4:15 PM EDT - 3 months ago

Danaher Appoints Jonathan Leiken as General Counsel

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Jul 24, 2025, 8:08 PM EDT - 3 months ago

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Danaher Q2 2025 Update

Jul 24, 2025, 3:30 PM EDT - 3 months ago

Danaher Q2 2025 Update

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

Jul 23, 2025, 9:50 AM EDT - 3 months ago

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 1:18 PM EDT - 3 months ago

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Cramer's Stop Trading: Danaher

Jul 22, 2025, 10:33 AM EDT - 3 months ago

Cramer's Stop Trading: Danaher

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Jul 22, 2025, 7:51 AM EDT - 3 months ago

Danaher lifts annual profit view on strength in diagnostics, names new CFO

Danaher Announces Transition Plan for Chief Financial Officer

Jul 22, 2025, 6:02 AM EDT - 3 months ago

Danaher Announces Transition Plan for Chief Financial Officer

Danaher Reports Second Quarter 2025 Results

Jul 22, 2025, 6:00 AM EDT - 3 months ago

Danaher Reports Second Quarter 2025 Results

45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs

Jul 17, 2025, 9:14 AM EDT - 3 months ago

45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs

AEP AGNC ALL FAF FLMI GDEN JAAA

Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside

Jun 30, 2025, 4:23 AM EDT - 4 months ago

Danaher: Biotech Momentum, Cost Cuts And Valuation Re-Rating Should Drive Upside

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Jun 27, 2025, 7:35 AM EDT - 4 months ago

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Jun 27, 2025, 7:30 AM EDT - 4 months ago

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Danaher: High Capex And Low Debt Despite Trump Legislation

Jun 19, 2025, 12:33 PM EDT - 4 months ago

Danaher: High Capex And Low Debt Despite Trump Legislation

Danaher Schedules Second Quarter 2025 Earnings Conference Call

Jun 17, 2025, 4:30 PM EDT - 4 months ago

Danaher Schedules Second Quarter 2025 Earnings Conference Call

Prosperity Partners Completes Acquisition of Danaher Attig & Plante

Jun 4, 2025, 9:00 AM EDT - 5 months ago

Prosperity Partners Completes Acquisition of Danaher Attig & Plante

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

Jun 2, 2025, 7:00 AM EDT - 5 months ago

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

Jun 2, 2025, 7:00 AM EDT - 5 months ago

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

May 29, 2025, 4:30 PM EDT - 5 months ago

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

AZN

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 5 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB GILD IBB ILMN NVS SDGR

Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)

May 15, 2025, 3:32 PM EDT - 5 months ago

Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)

Danaher to Present at Bank of America Securities Healthcare Conference

May 7, 2025, 4:15 PM EDT - 6 months ago

Danaher to Present at Bank of America Securities Healthcare Conference

Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity

May 6, 2025, 8:34 AM EDT - 6 months ago

Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity

Danaher: Q1 Beat Fails To Trigger Guidance Upgrade

May 2, 2025, 4:00 AM EDT - 6 months ago

Danaher: Q1 Beat Fails To Trigger Guidance Upgrade

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 6 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX GKOS INSM ISRG LLY RDNT

nathanfrederick
nathanfrederick Oct. 25 at 7:55 PM
$PFE $DHR High volume limit https://stocktwits.com/colbertquiller/message/633715057
0 · Reply
smartkarma
smartkarma Oct. 24 at 6:04 PM
$DHR | Danaher Corporation Is Powering Ahead With Explosive Bioprocessing Growth; But These Are The 4 Biggest Challenges Ahead! "Danaher Corporation's third-quarter 2025 earnings showcased a balanced performance underpinned by solid demand in certain sectors, yet offset by..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/danaher-corporation-is-powering-ahead-with-explosive-bioprocessing-growth-but-these-are-the-4-biggest-challenges-ahead
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 23 at 10:05 PM
$DHR Share Price: $222.64 Contract Selected: Nov 14, 2025 $225 Calls Buy Zone: $3.82 – $4.73 Target Zone: $7.24 – $8.85 Potential Upside: 79% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
IN0V8
IN0V8 Oct. 23 at 2:44 PM
$DHR Wells Fargo raises target price to $230 from $205
0 · Reply
UltimateNutz
UltimateNutz Oct. 23 at 1:27 PM
$DHR the revenue ‘beat’ of $40M was aided by a pull forward of about $100M per mgmt. would have been a tad light without it. <$210
0 · Reply
JarvisFlow
JarvisFlow Oct. 23 at 1:18 PM
Wells Fargo has updated their rating for Danaher ( $DHR ) to Equal-Weight with a price target of 230.
0 · Reply
ProfessorGamma
ProfessorGamma Oct. 23 at 12:44 AM
$PRSO $ABEV $CFLT $DHR How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 22 at 11:00 PM
Enter: $DHR NOV 14 2025 $220 CALLS Buy in Price: $6.20 - $8.00 Take Profit: $18.00 Stop Bleeding: $7.04 ROI Potential: 125% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 3:16 PM
TD Cowen has adjusted their stance on Danaher ( $DHR ), setting the rating to Buy with a target price of 250 → 260.
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 22 at 2:26 PM
$CDXS $DHR Interesting! https://www.aldevron.com/catalog-products/free-sample?utm_campaign=9437057-mrna-vx-tx&utm_term=codex-gmp-grade&utm_content=348143505&utm_medium=social&utm_source=linkedin&hss_channel=lcp-151339
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Oct. 22 at 1:11 PM
$DHR RSI: 59.13, MACD: 4.0021 Vol: 10.98, MA20: 203.65, MA50: 201.81 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 12:43 PM
Barclays updates rating for Danaher ( $DHR ) to Overweight, target set at 225 → 250.
0 · Reply
CPA_
CPA_ Oct. 22 at 12:10 AM
$DHR let’s gooooo!!!! Pump it up!!’
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 21 at 10:19 PM
Enter: $DHR NOV 14 2025 $225 CALLS Buy in Price: $2.97 - $6.60 Take Profit: $3.68 Stop Bleeding: $2.61 ROI Potential: 24% Exit Within: 2 Weeks https://moneygroup.us/alerts
0 · Reply
UltimateNutz
UltimateNutz Oct. 21 at 9:55 PM
$DHR even at $200 the 2026 PE is over 23 and still yield a PEG > 2. I think this a long way down potentially to go. Lots of room for China related jitters and no real catalysts.
0 · Reply
Nosh
Nosh Oct. 21 at 8:14 PM
$DHR When they spun off the water business...this stock just lost half it's appeal looking forward.
1 · Reply
TechTraderGrok
TechTraderGrok Oct. 21 at 8:06 PM
Bought $DHR at $220.92. From Grok: "Enter long on DHR's strong post-earnings gap up in a confirmed uptrend with price above EMA/SMA, positive reaction despite 0% surprise, targeting resistance near 252 over weeks, justified re-entry soon after 10/16 exit due to new favorable earnings outcome and momentum shift." https://www.techtrader.ai/grokwall/?post=15291&utm_source=dlvr.it&utm_medium=stocktwits
1 · Reply
UltimateNutz
UltimateNutz Oct. 21 at 7:17 PM
$DHR huge relative volume and pump at the open that was immediately sold off with relative volume steadily declining throughout the day. Going down.
0 · Reply
profit_guru
profit_guru Oct. 21 at 6:55 PM
$DHR - expect multiple price target cuts tomorrow on revenue guidance miss and valuation concerns…near term 200…imo
0 · Reply
UltimateNutz
UltimateNutz Oct. 21 at 6:12 PM
$DHR at this valuation, with no real catalysts to drive upward revisions, based on the CC and 17 of 22 with a buy rating and no sells - this could go a lot lower. Expecting a wave of buy to hold changes.
0 · Reply
Snihhga
Snihhga Oct. 21 at 5:00 PM
$DHR results bodes well for other names like $TKNO
1 · Reply
topstockalerts
topstockalerts Oct. 21 at 4:30 PM
$DHR keep an eye for today..
1 · Reply